Dexcom Inc at Robert W Baird Global Healthcare Conference Transcript
All right. Good morning. Why don't we get started? My name is Jeff Johnson. I'm the senior medical technology analyst at Baird. Our next presentation this morning is from DexCom, a leader in the $8 billion global continuous glucose monitoring market.
With us today from DexCom. We're happy to have VP of Investor Relations, Sean Christensen. And Sean, I know the rest of the team is on an executive off-site or something this week. So thanks for making the trip and doing us a solid here and still coming, so thanks for that. I'll turn it over to you if you have a few minutes of any prepared remarks you'd like to make, and then we'll move right into Q&A.
Yes, I'll just start off really quick and Jeff, thanks for hosting us today. We're thrilled to be here. It's an incredibly exciting year for DexCom and obviously for the industry. So we are in the midst of the launch of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |